We are live on ! Find out more
PRPO icon

Precipio

Positive
Neutral
Negative
Sentiment 3-Months
Positive 11.1%
Neutral 88.9%
Negative 0%

Positive
Zacks Investment Research
5 days ago
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?
Precipio and NeoGenomics take different approaches to cancer diagnostics, but which oncology stock looks more compelling now? Let's dive in.
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?
Neutral
GlobeNewsWire
1 month ago
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
NEW HAVEN, Conn., June 12, 2026 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately. Votes must be received by 11:59 p.m., Eastern Time, on June 14, 2026, to be voted at the Annual Meeting.
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
Neutral
GlobeNewsWire
1 month ago
Precipio to Present at the Planet MicroCap Las Vegas
NEW HAVEN, Conn., June 11, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc. (NASDAQ: PRPO) , announces that it will be presenting at the Planet MicroCap Las Vegas 2026 on Wednesday, June 17, 2026, at 9:00 AM (Local Time, 12:00pm EST) at the Bellagio Resort & Hotel. Ilan Danieli, CEO and Zaki Sabet, COO of Precipio will be hosting the presentation and answering questions at the conclusion.
Precipio to Present at the Planet MicroCap Las Vegas
Neutral
Zacks Investment Research
2 months ago
Precipio Stock Slips Post Q1 Earnings Despite Revenue Growth
PRPO's first-quarter 2026 sales are driven by pathology momentum, but CMS reimbursement cuts and higher spending squeeze margins and widen losses.
Precipio Stock Slips Post Q1 Earnings Despite Revenue Growth
Neutral
Seeking Alpha
2 months ago
Precipio, Inc. (PRPO) Q1 2026 Earnings Call Transcript
Precipio, Inc. (PRPO) Q1 2026 Earnings Call Transcript
Precipio, Inc. (PRPO) Q1 2026 Earnings Call Transcript
Neutral
GlobeNewsWire
2 months ago
Precipio Announces Q1 2026 Financial Results
Stable revenue performance driven by timing dynamics; expanding product pipeline expected to drive second-half growth Stable revenue performance driven by timing dynamics; expanding product pipeline expected to drive second-half growth
Precipio Announces Q1 2026 Financial Results
Neutral
GlobeNewsWire
2 months ago
Management team's 2025 market-based Options have vested
NEW HAVEN, Conn., May 13, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) announces that 2025 employee stock options granted to certain members of Precipio's management team vested last week because the Company's Common Stock price increased by more than 400% since the options were granted.
Management team's 2025 market-based Options have vested
Neutral
Zacks Investment Research
2 months ago
The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio
AI demand and pipeline growth headline top Zacks stock reports on NVIDIA, Mastercard and AbbVie.
The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio
Neutral
GlobeNewsWire
2 months ago
Precipio Announces Q1-2026 Shareholder Update Call
NEW HAVEN, Conn., May 06, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc.   (NASDAQ: PRPO) , will be hosting its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM ET.
Precipio Announces Q1-2026 Shareholder Update Call
Neutral
Seeking Alpha
3 months ago
Precipio, Inc. (PRPO) Q4 2025 Earnings Call Prepared Remarks Transcript
Precipio, Inc. (PRPO) Q4 2025 Earnings Call Prepared Remarks Transcript
Precipio, Inc. (PRPO) Q4 2025 Earnings Call Prepared Remarks Transcript